Skip to main content

Regorafenib in Treating Patients with Relapsed or Refractory, Advanced Myeloid Malignancies

Trial Status: Closed to Accrual

This phase I trial studies the side effects and best dose of regorafenib in treating patients with myeloid malignancies that have spread to other places in the body and have come back or do not respond to treatment. Regorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Inclusion Criteria

  • Diagnosis of relapsed/refractory advanced malignancies; specifically: * Patients relapsed refractory acute myeloid leukemia that have failed at least one line of prior therapy, * Patients with myelodysplastic syndrome that have failed hypomethylating agents, * Patients with myelofibrosis that have failed or are ineligible to receive ruxolitinib * Patients that have myelofibrosis on maximal tolerated doses of ruxolitinib, who are unable to discontinue ruxolitinib, are eligible if; ** They have been on stable dose for 1 month and continue to have residual symptoms, splenomegaly or inadequately controlled blood counts * Patients with chronic myelomonocytic leukemia that have failed hypomethylating agents * Patients with advanced or unclassified myeloproliferative neoplasms on maximal tolerated doses of ruxolitinib, who are unable to discontinue ruxolitinib, are eligible if; ** They have been on stable dose for 1 month and continue to have residual symptoms, splenomegaly or inadequately controlled blood counts
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Able to provide informed consent
  • Subjects (men and women) of childbearing potential must agree to use adequate contraception beginning at the signing of the informed consent form (ICF) until at least 2 months after the last dose of study drug; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate
  • Able to swallow and retain oral medication
  • Total bilirubin =< 1.5 x the upper limits of normal (ULN) except for patients with Gilbert’s disease
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
  • Alkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver or bone involvement of their cancer)
  • Serum creatinine =< 1.5 x the ULN
  • International normalized ratio (INR)/partial thromboplastin time (PTT) =< 1.5 x ULN; (subjects who are prophylactically treated with an agent such as warfarin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in coagulation parameters exists)

Exclusion Criteria

  • Previous assignment to treatment during this study; subjects permanently withdrawn from study participation will not be allowed to re-enter the study
  • Systemic antineoplastic therapy in the past 14 days (excluding hydroxyurea)
  • Uncontrolled hypertension (systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg on repeated measurement) despite optimal medical management
  • Active or clinically significant cardiac disease including: * Congestive heart failure – New York Heart Association (NYHA) > class II * Active coronary artery disease * Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin * Unstable angina (anginal symptoms at rest), new-onset angina within 3 months before randomization, or myocardial infarction within 6 months before randomization
  • Evidence or history of bleeding diathesis or coagulopathy
  • Eligible for, have a suitable donor, and are willing to undergo hematopoietic stem cell transplantation (HSCT)
  • Any hemorrhage or bleeding event >= National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 3 within 4 weeks prior to start of study medication
  • Thrombotic, embolic, venous or arterial events, such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months of informed consent
  • Previously untreated or concurrent cancer that is distinct in primary site or histology except cervical cancer in-situ, treated ductal carcinoma in situ of the breast, curatively treated non-melanoma skin carcinoma, noninvasive aerodigestive neoplasms or superficial bladder tumor; subjects surviving a cancer that was curatively treated and without evidence of disease for more than 3 years before registration are allowed; all cancer treatments for concurrent cancers must be completed at least 3 years prior to registration
  • Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy
  • Presence of a non-healing wound, non-healing ulcer or bone fracture
  • Major surgical procedure or significant traumatic injury within 28 days before start of study medication
  • Renal failure requiring hemo-or peritoneal dialysis
  • Seizure disorder requiring medication
  • Persistent proteinuria >= grade 3 NCI-CTCAE version (v) 4.0 (> 3.5 g/24 hours [hrs], measured by urine protein: creatinine ratio on a random urine sample)
  • Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
  • Pleural effusion or ascites that causes respiratory compromise (>= NCI-CTCAE version 4.0 grade 2 dyspnea)
  • History of organ allograft (including corneal transplant) except stem cell transplants
  • Known or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial
  • Any malabsorption condition
  • Women who are pregnant or breast-feeding, or intend to become pregnant during the study; women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of study drug; post-menopausal women (defined as no menses for at least 1 year) and surgically sterilized women are not required to undergo a pregnancy test
  • Substance abuse, medical, psychological or social conditions that may interfere with the subject’s participation in the study or evaluation of the study results
  • Presence of unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v4.03 grade 0 or 1 with the exception of alopecia; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by regorafenib (e.g. hearing loss, neuropathy) may be included after consultation with the principal investigator
  • Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements


Massachusetts General Hospital Cancer Center
Contact: Gabriela Soriano Hobbs
Phone: 617-643-1754


I. To assess safety and tolerability of regorafenib in patients with advanced myeloid malignancies.

II. To define a maximum tolerated dose (MTD) of regorafenib and to characterize its dose-limiting toxicities (DLTs) in patients with advanced myeloid malignancies.


I. To assess the pharmacodynamics of regorafenib via changes in known regorafenib targets such as vascular endothelial growth factor (VEGF), soluble VEGFR1, basic fibroblast growth factor (bFGF), VEGF-C, VEGF-D, sVEGFR2, placental-derived growth factor (P1GF), soluble TIE-2, soluble (s)- c-KIT, stromal-derived factor 1 alpha (SDF1 alpha), as well as inflammatory biomarkers and markers of tumor hypoxia and correlate changes in these with treatment response.

II. To assess treatment response, progression-free and overall survival in patients with acute myeloid leukemia (AML) who receive regorafenib.

III. To measure changes in specific markers of allele burden, when applicable (such as JAK2 V617F allele burden, FLT3-ITD, RAS, IDH and specific mutations found in each patient sample) and correlate them with treatment response.

OUTLINE: This is a dose-escalation study.

Patients receive regorafenib orally (PO) once daily (QD) on days 1-21. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 12 months.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Dana-Farber Harvard Cancer Center

Principal Investigator
Gabriela Soriano Hobbs

  • Primary ID 16-464
  • Secondary IDs NCI-2017-00563
  • ID NCT03042689